in case you're interesting in the causal diagram for the mediation modelling for this: far from proven, but certainly does raise some questions about a potential advantage of IL-23 inhibitors in a crowded PsA market #EULAR2022 @RheumNow https://t.co/bSuE3tDHUO

Top Influencers of #EULAR2022: @eular_org @EMEUNET @RheumNow @ARD_BMJ @RichardPAConway @Yuz6Yusof @ProftDr More 📊 https://t.co/fUfohEZAoX

• #EULAR2022 - EULAR 2022 - Social Media Analytics and Transcripts

Interesting, NWA by Dougados et al shows both Tofa and ADA may benefit pain in those who have controlled inflammatory component. ?real effect vs imperfect measures @RheumNow #EULAR2022 OP0052 https://t.co/aYBTaSDa3v https://t.co/dkLv1l5tFy

• EULAR Abstract Archive

#POS0065 #EULAR2022 What is the nature of ILD progression in #Sjogren and is it mostly stable? A cohort study in Oslo (N=702) showed after 15 yrs follow-up, 45% had radiographic progression. Hence, need to monitor lung function test @RheumNow https://t.co/ga7qer27ks

#POS0263 #EULAR2022 In #rituximab-treated RMD patients with undetectable humoral response to primary #COVID 💉, a study (N=84) found Re-Vaccination with mRNA (2 shots) was better than a Booster (1 shot). Lend support for current approach: 2 + 3rd Primary + Booster @RheumNow https://t.co/AH0wpVKbHc

Burja et al. Dimethyl alpha-ketoglutarate has anti-inflammatory and anti-fibrotic effects on explanted systemic sclerosis skin. @RheumNow #EULAR2022 OP0095 https://t.co/PSbnVh6uta https://t.co/2ij9HgoU6Q

• EULAR Abstract Archive

RheumNow Coverage of #EULAR2022 Presents Live Expert Discussions https://t.co/FeE0WfXw1z

• https://twitter.com/i/broadcasts/1ypKdEBWXMnGW

Phase 3 RCT upadacitinib in nrAxSpA. Clinical (ASAS40), PRO, and radiologic response seen at week 14 vs placebo @RheumNow #EULAR2022 OP0016 https://t.co/s3Vf4QiiAD https://t.co/gzlxZ3sxHF

• EULAR Abstract Archive

#EULAR2022 OP0073: Gender-specific assessment for MRI imaging criteria ⭐️Sex differences in axSpA - disease presentations, jt biomechanics, diagnostic delay in ♀️ ⭐️Higher fat metaplasia in ♂️, Sclerosis in ♀️ ⭐️Ankylosis much higher in ♂️ (DOR 40!) @Rheumnow

#What’sHot? Axial PsA cohort as some drugs seem to work differently in axPsA vs axSpA Less HLAB27+, less male, 17% isolated axial in PsA #OP0026 @RheumNow #EULAR2022 @eular_org https://t.co/I0azSymVrr

Intra-articular morphine in knee arthritis. WHAT!? Not-surprisingly it doesn't work. Inferior to steroid and same as placebo. Still kudos to Haibel et al for answering this question @RheumNow #EULAR2022 OP0050 https://t.co/zjY36V9OCS https://t.co/j67omCQCxI

• EULAR Abstract Archive

#POS0086PARE #EULAR2022 What #lupus symptoms/target mattered most to the patients?A survey in 342 found reduction in joint pain, rash & non-joint pain as most important. Reduced infection risk was the least. Important to be aware in assessing patients & guide studies @RheumNow https://t.co/pGXxklj1mt

Minimal disease activity achivement by PsA domain over 2y, in guselkumab phase 3 Everyone goes on about skin efficacy with guselkumab, but pretty good early on for enthesitis & swollen joints too... has challenged my uninformed thinking! POS1067 #EULAR2022 #IL23 @RheumNow https://t.co/chCWeFd05o

↘️Education level🟰↗️risk of clinical RA in at risk patients. HR=1.8 although partially explained by ↗️ MRI inflammation at Dx. Adjusted on smoking status, age and BMI. Shall we follow this group of patients more closely? OP0035 #EULAR2022 @RheumNow https://t.co/8EJZpaxn3k

🔜 Remission in PsA : the earlier the better ⏰ Dutch cohort (DEPAR) 300+pts Failure to achieve MDA 1yr post diagnosis 🧨worst QoL yr 1️⃣2️⃣&3️⃣ 🧨↗️bioDMARDs use over time 🧨no recovery #OP0028 #EULAR2022 @RheumNow https://t.co/IS6ySIQvBP